19 May 2013
Keywords: sankyo, nbi, cross, licensing, deal, nippon, boehringer
Article | 31 January 1994
Sankyo and Nippon Boehringer Ingelheim have entered into a
cross-licensing agreement for the parallel marketing of Sankyo's Acecol
(temocapril HCl) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
31 January 1994
17 May 2013
© 2013 thepharmaletter.com